Francisco Visiedo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Francisco Visiedo has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Fernando Bugatto
Area of Obstetrics and Gynaecology, Department of Child and Mother Health and Radiology, School of Medicine, University of Cádiz, 11009 Cádiz, Spain
12 shared publications - Rosa María Mateos
Research Unit, Biomedical Research and Innovation Institute of Cadiz (INiBICA), Puerta del Mar University Hospital, 11009 Cadiz, Spain
11 shared publications - Alfonso Maria Lechuga-Sancho
Servicio de Pediatría, Hospital Universitario Puerta del Mar, Cádiz, Spain
6 shared publications - Ana Saez-Benito
Clinical Analysis Department, Puerta del Mar University Hospital, Cádiz, Spain
5 shared publications - Germán Perdomo
Instituto de Biomedicina y Genética Molecular (Consejo Superior de Investigaciones Científicas-Universidad de Valladolid), 47003 Valladolid, Spain
5 shared publications - Luis Vázquez-Fonseca
Inflammation and Metabolic Syndrome in Pregnancy Group (CO25), Biomedical Research and Innovation Institute of Cádiz (INiBICA), 11009 Cádiz, Spain
5 shared publications
Latest Publications
- Open Access
- 21 November 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (12) , 1694
Plasma Inorganic Polyphosphate Is Associated with Gestational Diabetes Mellitus in Early Pregnancy: Evidence from Two Independent Cross-Sectional Populations
Plasma inorganic polyphosphate (polyP) is a biologically active phosphate polymer implicated in coagulation, inflammation, and cellular metabolism. However, circulating polyP has not been well characterized during pregnancy, and its relationship with gestational diabetes mellitus (GDM) remains unclear. Here, we evaluated plasma polyP concentrations in two independent retrospective cross-sectional cohorts of pregnant women studied during the first and third trimesters. A total of 101 women were included: 40 in the first-trimester cohort and 61 in the third-trimester cohort. Plasma polyP was quantified specifically using an enzymatic assay based on recombinant Saccharomyces cerevisiae exopolyphosphatase and normalized to protein content. PolyP concentrations were higher in the first-trimester cohort than in the third-trimester cohort. Within the first-trimester cohort, women with GDM had significantly higher polyP concentrations than women without GDM. In the third-trimester cohort, women with GDM had significantly lower polyP concentrations than controls. Exploratory receiver operating characteristic (ROC) analyses suggested a potential discriminatory signal of plasma polyP concentrations in relation to GDM status in both cohorts. Overall, the findings indicate that circulating polyP concentrations vary according to gestational stage and GDM status. Prospective longitudinal studies with larger, independently validated cohorts are needed to determine the temporal behavior, biological determinants, and potential clinical relevance of circulating polyP during pregnancy.
- 21 November 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (12) , 1694
Open AccessPlasma Inorganic Polyphosphate Is Associated with Gestational Diabetes Mellitus in Early Pregnancy: Evidence from Two Independent Cross-Sectional Populations
Plasma inorganic polyphosphate (polyP) is a biologically active phosphate polymer implicated in coagulation, inflammation, and cellular metabolism. However, circulating polyP has not been well characterized during pregnancy, and its relationship with gestational diabetes mellitus (GDM) remains unclear. Here, we evaluated plasma polyP concentrations in two independent retrospective cross-sectional cohorts of pregnant women studied during the first and third trimesters. A total of 101 women were included: 40 in the first-trimester cohort and 61 in the third-trimester cohort. Plasma polyP was quantified specifically using an enzymatic assay based on recombinant Saccharomyces cerevisiae exopolyphosphatase and normalized to protein content. PolyP concentrations were higher in the first-trimester cohort than in the third-trimester cohort. Within the first-trimester cohort, women with GDM had significantly higher polyP concentrations than women without GDM. In the third-trimester cohort, women with GDM had significantly lower polyP concentrations than controls. Exploratory receiver operating characteristic (ROC) analyses suggested a potential discriminatory signal of plasma polyP concentrations in relation to GDM status in both cohorts. Overall, the findings indicate that circulating polyP concentrations vary according to gestational stage and GDM status. Prospective longitudinal studies with larger, independently validated cohorts are needed to determine the temporal behavior, biological determinants, and potential clinical relevance of circulating polyP during pregnancy.
- Open Access
Does Looking at the Placenta Improve First-Trimester Screening? Placental Volume, Vascular Indices and Fetal Growth Disorders in an Unselected Cohort
Background/Objectives: Fetal growth disorders and hypertensive disorders of pregnancy share pathophysiological pathways rooted in impaired first-trimester placentation. We asked whether three-dimensional placental volume and the VOCAL vascular indices add prognostic information to first-trimester screening and how repeatable and setting-dependent they are. Methods: A prospective cohort of 445 singleton pregnancies was scanned at 11+0–13+6 weeks, twice each at two pulse repetition frequencies (2.3 and 0.9 kHz). Markers were converted to crown–rump-length-adjusted z-scores. The primary analysis tested the incremental value of volume over clinical risk factors plus PAPP-A for a composite of hypertensive disorders, fetal growth restriction or small-for-gestational-age birth, with bootstrap optimism correction (1000 resamples). Results: The composite outcome occurred in 69/407 women (17.0%). Volume was repeatable (intraclass correlation 0.90) and not measurably associated with maternal adiposity, whereas the indices differed threefold between paired acquisitions obtained at different settings, varied between operators and fell with body mass index. Volume was associated with the outcome independently of clinical risk factors and PAPP-A (likelihood-ratio p < 0.001; odds ratio 0.55 per SD, 95% CI 0.41–0.74) and of the combined preeclampsia-screening components; the corresponding increase in the area under the curve was small (optimism-corrected 0.59 to 0.66) and not significant by DeLong’s test (p = 0.13), and calibration slopes indicated overfitting. The indices showed no consistent incremental value. Small placentas preceded growth restriction (composite outcome 45% below the study-derived 5th centile), and large placentas preceded large-for-gestational-age birth. With four cases of preeclampsia, the study is uninformative for preeclampsia-specific prediction. Conclusions: First-trimester placental volume is a reproducible marker, not measurably associated with maternal adiposity, which was independently associated with fetal growth disorders in this cohort; the resulting gain in discrimination was small and its clinical value is unproven. Aspirin use after screening was not recorded. External validation, assessment of reproducibility between operators and analysts, and evaluation of clinical utility are required before any use in practice. The vascular indices are acquisition- and habitus-dependent and showed no consistent incremental prognostic value.
Open AccessDoes Looking at the Placenta Improve First-Trimester Screening? Placental Volume, Vascular Indices and Fetal Growth Disorders in an Unselected Cohort
Background/Objectives: Fetal growth disorders and hypertensive disorders of pregnancy share pathophysiological pathways rooted in impaired first-trimester placentation. We asked whether three-dimensional placental volume and the VOCAL vascular indices add prognostic information to first-trimester screening and how repeatable and setting-dependent they are. Methods: A prospective cohort of 445 singleton pregnancies was scanned at 11+0–13+6 weeks, twice each at two pulse repetition frequencies (2.3 and 0.9 kHz). Markers were converted to crown–rump-length-adjusted z-scores. The primary analysis tested the incremental value of volume over clinical risk factors plus PAPP-A for a composite of hypertensive disorders, fetal growth restriction or small-for-gestational-age birth, with bootstrap optimism correction (1000 resamples). Results: The composite outcome occurred in 69/407 women (17.0%). Volume was repeatable (intraclass correlation 0.90) and not measurably associated with maternal adiposity, whereas the indices differed threefold between paired acquisitions obtained at different settings, varied between operators and fell with body mass index. Volume was associated with the outcome independently of clinical risk factors and PAPP-A (likelihood-ratio p < 0.001; odds ratio 0.55 per SD, 95% CI 0.41–0.74) and of the combined preeclampsia-screening components; the corresponding increase in the area under the curve was small (optimism-corrected 0.59 to 0.66) and not significant by DeLong’s test (p = 0.13), and calibration slopes indicated overfitting. The indices showed no consistent incremental value. Small placentas preceded growth restriction (composite outcome 45% below the study-derived 5th centile), and large placentas preceded large-for-gestational-age birth. With four cases of preeclampsia, the study is uninformative for preeclampsia-specific prediction. Conclusions: First-trimester placental volume is a reproducible marker, not measurably associated with maternal adiposity, which was independently associated with fetal growth disorders in this cohort; the resulting gain in discrimination was small and its clinical value is unproven. Aspirin use after screening was not recorded. External validation, assessment of reproducibility between operators and analysts, and evaluation of clinical utility are required before any use in practice. The vascular indices are acquisition- and habitus-dependent and showed no consistent incremental prognostic value.
- Open Access
Mitochondrial Dysfunction Combined with Elevated CoQ10 Levels Specifically in Placental Cytotrophoblasts Suggests a Role for Mitophagy in Preeclampsia
Preeclampsia is a serious pregnancy disorder of unknown etiology. One of its cellular hallmarks is increased mitochondrial dysfunction in placental tissue. Further investigation into this aspect may help elucidate the molecular basis of preeclampsia. A total of 24 pregnant women who delivered by cesarean section participated in the study: n = 13 controls and n = 11 diagnosed with preeclampsia. Maternal blood samples were collected to assess the biochemical profile, and demographic and clinical data were recorded. Placental trophoblast samples were processed to isolate mitochondria and perform molecular biology assays. Women with preeclampsia exhibited the characteristic clinical features of the disease, along with biochemical alterations consistent with an inflammatory process. A significant decrease (73%) in mitochondrial DNA (mtDNA) copy number in trophoblastic tissue and a reduction in citrate synthase (CS) activity (−51%) in cytotrophoblast mitochondria-enriched fractions were observed in preeclampsia, indicating mitochondrial dysfunction accompanied by a loss of functional mitochondrial mass. In addition, we detected a marked decrease in MnSOD levels (−32%), together with an increase in the LC3II/LC3I ratio (47%) in cytotrophoblast mitochondria-enriched fractions, supporting the presence of mitochondrial alterations and suggesting the possible activation of mitophagy specifically in this cell type. Moreover, coenzyme Q10 (CoQ10) levels were elevated by 31% in trophoblastic villi. A pronounced 2.5-fold increase in CoQ10 normalized to CS activity (CoQ10/CS) was detected specifically in cytotrophoblasts from preeclamptic placentas. Importantly, we did not observe these alterations in the syncytiotrophoblast. In conclusion, preeclampsia is associated with mitochondrial dysfunction and increased CoQ10 levels normalized to CS activity, specifically in cytotrophoblast mitochondria, with findings being consistent with a possible involvement of mitophagy in this cell type. These findings suggest that cytotrophoblast mitochondrial metabolism may be more affected in preeclampsia compared with syncytiotrophoblasts, and that CoQ10 accumulation together with the possible activation of mitophagy may represent cellular defense mechanisms. Due to the limitations of the study, it should be considered exploratory and hypothesis-generating, and its results should be regarded as preliminary.
Open AccessMitochondrial Dysfunction Combined with Elevated CoQ10 Levels Specifically in Placental Cytotrophoblasts Suggests a Role for Mitophagy in Preeclampsia
Preeclampsia is a serious pregnancy disorder of unknown etiology. One of its cellular hallmarks is increased mitochondrial dysfunction in placental tissue. Further investigation into this aspect may help elucidate the molecular basis of preeclampsia. A total of 24 pregnant women who delivered by cesarean section participated in the study: n = 13 controls and n = 11 diagnosed with preeclampsia. Maternal blood samples were collected to assess the biochemical profile, and demographic and clinical data were recorded. Placental trophoblast samples were processed to isolate mitochondria and perform molecular biology assays. Women with preeclampsia exhibited the characteristic clinical features of the disease, along with biochemical alterations consistent with an inflammatory process. A significant decrease (73%) in mitochondrial DNA (mtDNA) copy number in trophoblastic tissue and a reduction in citrate synthase (CS) activity (−51%) in cytotrophoblast mitochondria-enriched fractions were observed in preeclampsia, indicating mitochondrial dysfunction accompanied by a loss of functional mitochondrial mass. In addition, we detected a marked decrease in MnSOD levels (−32%), together with an increase in the LC3II/LC3I ratio (47%) in cytotrophoblast mitochondria-enriched fractions, supporting the presence of mitochondrial alterations and suggesting the possible activation of mitophagy specifically in this cell type. Moreover, coenzyme Q10 (CoQ10) levels were elevated by 31% in trophoblastic villi. A pronounced 2.5-fold increase in CoQ10 normalized to CS activity (CoQ10/CS) was detected specifically in cytotrophoblasts from preeclamptic placentas. Importantly, we did not observe these alterations in the syncytiotrophoblast. In conclusion, preeclampsia is associated with mitochondrial dysfunction and increased CoQ10 levels normalized to CS activity, specifically in cytotrophoblast mitochondria, with findings being consistent with a possible involvement of mitophagy in this cell type. These findings suggest that cytotrophoblast mitochondrial metabolism may be more affected in preeclampsia compared with syncytiotrophoblasts, and that CoQ10 accumulation together with the possible activation of mitophagy may represent cellular defense mechanisms. Due to the limitations of the study, it should be considered exploratory and hypothesis-generating, and its results should be regarded as preliminary.
- Open Access
Polyhydramnios at Term in Gestational Diabetes: Should We Be Concerned?
Background/Objectives: Pregnancies complicated by idiopathic polyhydramnios are linked to a heightened risk of numerous maternal and perinatal complications. We aim to study the implications of polyhydramnios in term pregnancies complicated with gestational diabetes mellitus (GDM). Methods: A prospective cohort study including 340 GDM cases was conducted. An ultrasound scan was conducted at term between 37 and 40 weeks and amniotic fluid volume (AFV) was assessed by measuring the amniotic fluid index (AFI) and the single deepest pocket (SDP). Maternal demographics and obstetric and perinatal outcomes were evaluated after delivery. We performed comparisons between groups with normal AFV and polyhydramnios (AFI ≥ 24 cm or SDP ≥ 8 cm), and between groups with normal and increased AFV (AFI or SDP ≥ 75th centile). A multivariate logistic regression analysis was performed to study association between AVF measurements and adverse maternal and perinatal outcomes. Results: We found that women with GDM and polyhydramnios at term had a higher risk of maternal (54.3 vs. 27.5%, p < 0.001) and perinatal adverse outcomes (65.7% vs. 46.5%, p < 0.03). The increased AFV group showed a higher risk of fetal overgrowth (LGA: 21.4% vs. 8.2%, p < 0.001 and macrosomia: 19.8% vs. 5.4%, p < 0.001, respectively) and a lesser risk of delivering an SGA fetus (6.3% vs. 13.6%, respectively). Both AFI and SDP showed a significant correlation with newborn weight (r = 0.27; p < 0.001 and r = 0.28; p < 0.001, respectively) and newborn centile (r = 0.26; p < 0.001 and r = 0.26 for both). Subsequent to conducting a multivariate logistic regression analysis adjusted for pregestational BMI, nulliparity, and insulin treatment, both AFI and SDP were significantly associated with perinatal complications, but AFI showed a stronger association with fetal overgrowth (aOR 1.11; p = 0.004 for a LGA fetus and aOR 1.12; p = 0.002 for macrosomia) and with lower risk of delivering an SGA fetus (aOR 0.89; p = 0.009) or IUGR fetus (aOR 0.86; p = 0.03). ROC analysis showed a poor diagnostic performance of both AFI and SDP for identifying macrosomia (AUC 0.68 for AFI, and 0.65 for SDP). Conclusions: Detection of polyhydramnios at term, whether using AFI or SDP, identifies a subgroup of women with gestational diabetes with higher risks of obstetric and perinatal complications. Cases with increased AFV (AFI ≥ 18 cm or SDP ≥ 6.5 cm) are also associated with an increased risk of fetal overgrowth and may require more intensive monitoring for management and optimal delivery timing, with the aim of improve perinatal outcomes.
Open AccessPolyhydramnios at Term in Gestational Diabetes: Should We Be Concerned?
Background/Objectives: Pregnancies complicated by idiopathic polyhydramnios are linked to a heightened risk of numerous maternal and perinatal complications. We aim to study the implications of polyhydramnios in term pregnancies complicated with gestational diabetes mellitus (GDM). Methods: A prospective cohort study including 340 GDM cases was conducted. An ultrasound scan was conducted at term between 37 and 40 weeks and amniotic fluid volume (AFV) was assessed by measuring the amniotic fluid index (AFI) and the single deepest pocket (SDP). Maternal demographics and obstetric and perinatal outcomes were evaluated after delivery. We performed comparisons between groups with normal AFV and polyhydramnios (AFI ≥ 24 cm or SDP ≥ 8 cm), and between groups with normal and increased AFV (AFI or SDP ≥ 75th centile). A multivariate logistic regression analysis was performed to study association between AVF measurements and adverse maternal and perinatal outcomes. Results: We found that women with GDM and polyhydramnios at term had a higher risk of maternal (54.3 vs. 27.5%, p < 0.001) and perinatal adverse outcomes (65.7% vs. 46.5%, p < 0.03). The increased AFV group showed a higher risk of fetal overgrowth (LGA: 21.4% vs. 8.2%, p < 0.001 and macrosomia: 19.8% vs. 5.4%, p < 0.001, respectively) and a lesser risk of delivering an SGA fetus (6.3% vs. 13.6%, respectively). Both AFI and SDP showed a significant correlation with newborn weight (r = 0.27; p < 0.001 and r = 0.28; p < 0.001, respectively) and newborn centile (r = 0.26; p < 0.001 and r = 0.26 for both). Subsequent to conducting a multivariate logistic regression analysis adjusted for pregestational BMI, nulliparity, and insulin treatment, both AFI and SDP were significantly associated with perinatal complications, but AFI showed a stronger association with fetal overgrowth (aOR 1.11; p = 0.004 for a LGA fetus and aOR 1.12; p = 0.002 for macrosomia) and with lower risk of delivering an SGA fetus (aOR 0.89; p = 0.009) or IUGR fetus (aOR 0.86; p = 0.03). ROC analysis showed a poor diagnostic performance of both AFI and SDP for identifying macrosomia (AUC 0.68 for AFI, and 0.65 for SDP). Conclusions: Detection of polyhydramnios at term, whether using AFI or SDP, identifies a subgroup of women with gestational diabetes with higher risks of obstetric and perinatal complications. Cases with increased AFV (AFI ≥ 18 cm or SDP ≥ 6.5 cm) are also associated with an increased risk of fetal overgrowth and may require more intensive monitoring for management and optimal delivery timing, with the aim of improve perinatal outcomes.
- Open Access
Optimization of the Enzymatic Extraction of Naringenin from Pink Grapefruit Pulp (Citrus × paradisi Macfad.)
Naringenin is one of the main phenolic compounds found in grapefruit (Citrus × paradisi Macfad.). This compound is known for its therapeutical properties as an antioxidant, antidiabetic, antihyperlipidemic and antineoplastic agent. In order to enable the development of drugs based on this compound, an appropriate extraction method needs to be developed. For this study, enzymatic extraction was chosen, as it is a cheap and green extraction method. Optimal extraction conditions (pH, temperature, agitation, solvent composition, sample-to-solvent ratio and enzyme-to-sample ratio) were determined through a Plackett–Burman and a Box–Behnken design, resulting in pH 6.0, 40 °C, 50 rpm, 20% EtOH, 0.2 g sample per 15 mL solvent and 1000 U/g. Once extraction conditions were determined, a single-factor experiment was performed under optimal conditions to determine extraction time, which resulted in 10 min per extraction. Finally, repeatability and intermediate precision were evaluated through naringenin quantification. Good values were obtained for both parameters (1.80% and 2.05%, respectively). Furthermore, extracts presented significant amount of naringenin (0.18 ± 0.02 mg/g).
Open AccessOptimization of the Enzymatic Extraction of Naringenin from Pink Grapefruit Pulp (Citrus × paradisi Macfad.)
Naringenin is one of the main phenolic compounds found in grapefruit (Citrus × paradisi Macfad.). This compound is known for its therapeutical properties as an antioxidant, antidiabetic, antihyperlipidemic and antineoplastic agent. In order to enable the development of drugs based on this compound, an appropriate extraction method needs to be developed. For this study, enzymatic extraction was chosen, as it is a cheap and green extraction method. Optimal extraction conditions (pH, temperature, agitation, solvent composition, sample-to-solvent ratio and enzyme-to-sample ratio) were determined through a Plackett–Burman and a Box–Behnken design, resulting in pH 6.0, 40 °C, 50 rpm, 20% EtOH, 0.2 g sample per 15 mL solvent and 1000 U/g. Once extraction conditions were determined, a single-factor experiment was performed under optimal conditions to determine extraction time, which resulted in 10 min per extraction. Finally, repeatability and intermediate precision were evaluated through naringenin quantification. Good values were obtained for both parameters (1.80% and 2.05%, respectively). Furthermore, extracts presented significant amount of naringenin (0.18 ± 0.02 mg/g).
- Open Access
- 3 February 2023
- Published by MDPI AG in Antioxidants
- Vol. 12 (2) , 369
Optimizing an Enzymatic Extraction Method for the Flavonoids in Moringa (Moringa oleifera Lam.) Leaves Based on Experimental Designs Methodologies
Moringa oleifera Lam. is known to have significant antioxidant properties. Because of this, the development of an optimal extraction method is crucial to obtain pharmacological products based on the bioactive compounds produced by this tree. Through a Plackett–Burman and a Box–Behnken design, enzymatic extraction conditions (temperature, agitation, solvent pH and composition, sample-to-solvent ratio, enzyme-to-sample ratio and extraction time) have been optimized using normalized areas (UA/g) as response variable and relative mass (mg/g) as quantification variable. Extractions were performed in an incubator, where all the extraction conditions could be digitally controlled. Thus, 58.9 °C, 50 rpm, 4.0 pH, 32.5% EtOH, 0.2 g sample in 15 mL solvent and 106 U/g were established as the optimal extraction conditions for the extraction with a mix of pectinases coming from Aspergillus niger. Under these optimal conditions, two-minute extractions were performed and evaluated through a single factor design. The enzymatic extraction method demonstrated its suitability to produce extracts with good antioxidant power (antioxidant activity 4.664 ± 0.059 mg trolox equivalent/g sample and total phenolic compounds 6.245 ± 0.101 mg gallic acid equivalent/g sample). The method was also confirmed to have good repeatability (1.39%) and intermediate precision (2.37%) levels.
- 3 February 2023
- Published by MDPI AG in Antioxidants
- Vol. 12 (2) , 369
Open AccessOptimizing an Enzymatic Extraction Method for the Flavonoids in Moringa (Moringa oleifera Lam.) Leaves Based on Experimental Designs Methodologies
Moringa oleifera Lam. is known to have significant antioxidant properties. Because of this, the development of an optimal extraction method is crucial to obtain pharmacological products based on the bioactive compounds produced by this tree. Through a Plackett–Burman and a Box–Behnken design, enzymatic extraction conditions (temperature, agitation, solvent pH and composition, sample-to-solvent ratio, enzyme-to-sample ratio and extraction time) have been optimized using normalized areas (UA/g) as response variable and relative mass (mg/g) as quantification variable. Extractions were performed in an incubator, where all the extraction conditions could be digitally controlled. Thus, 58.9 °C, 50 rpm, 4.0 pH, 32.5% EtOH, 0.2 g sample in 15 mL solvent and 106 U/g were established as the optimal extraction conditions for the extraction with a mix of pectinases coming from Aspergillus niger. Under these optimal conditions, two-minute extractions were performed and evaluated through a single factor design. The enzymatic extraction method demonstrated its suitability to produce extracts with good antioxidant power (antioxidant activity 4.664 ± 0.059 mg trolox equivalent/g sample and total phenolic compounds 6.245 ± 0.101 mg gallic acid equivalent/g sample). The method was also confirmed to have good repeatability (1.39%) and intermediate precision (2.37%) levels.
- Open Access
First Trimester Evaluation of Maternal Visceral Fat and Its Relationship with Adverse Pregnancy Outcomes
Obese women are more likely to experience pregnancy complications. The distribution of fat, and more particularly the rise in visceral fat, is well established to be more closely linked to the onset of cardiovascular disease and metabolic syndrome than obesity itself. We aim to examine the relationship between maternal visceral fat assessment in the first trimester and the appearance of adverse pregnancy outcomes. A prospective cohort study including 416 pregnant women was conducted. During the first trimester scan (11–13 + 6 weeks), all individuals had their visceral fat and subcutaneous thicknesses measured by ultrasonography. Blood samples were obtained, and maternal demographics and clinical information were documented. After delivery, the obstetric outcomes were evaluated. We contrasted two groups: one with healthy pregnancies and the other with adverse pregnancy outcomes (APO), defined as the development of at least one of the following complications: gestational diabetes mellitus, hypertensive disorders of pregnancy, abnormal fetal growth, preterm delivery or preterm premature rupture of membranes. Median maternal age was 33 and 34 years old for the uncomplicated and adverse pregnancy outcomes groups, respectively. We found that women with adverse pregnancy outcomes had higher VFT (median 30 vs. 26.5 mm, p = 0.001) and SFT (median 18.9 vs. 17.1 mm, p = 0.03). However, the visceral/subcutaneous fat ratio was not statistically different between groups. Finally, we performed a subanalysis for metabolic and placental vascular dysfunction complications. After performing a multivariate logistic regression analysis adjusted for maternal age, smoking, and mean arterial pressure, both the VFT (aOR 1.03, p < 0.001) and the ratio of visceral/subcutaneous fat (aOR 1.37, p = 0.04) were significantly associated with the development of adverse pregnancy outcomes; however, the associations of VFT and the VFT-to-SFT ratio were higher for the occurrence of gestational diabetes (aOR 1.07, p < 0.001; aOR 2.09, p = 0.001; respectively) and showed no relationships with placental complications. When conducting a first-trimester ultrasound assessment, sonographers may measure VFT without additional time or cost involved. Identification of pregnant women with increased VFT (>37 mm) may benefit from a close follow-up, especially for the development of gestational diabetes, independent of BMI.
Open AccessFirst Trimester Evaluation of Maternal Visceral Fat and Its Relationship with Adverse Pregnancy Outcomes
Obese women are more likely to experience pregnancy complications. The distribution of fat, and more particularly the rise in visceral fat, is well established to be more closely linked to the onset of cardiovascular disease and metabolic syndrome than obesity itself. We aim to examine the relationship between maternal visceral fat assessment in the first trimester and the appearance of adverse pregnancy outcomes. A prospective cohort study including 416 pregnant women was conducted. During the first trimester scan (11–13 + 6 weeks), all individuals had their visceral fat and subcutaneous thicknesses measured by ultrasonography. Blood samples were obtained, and maternal demographics and clinical information were documented. After delivery, the obstetric outcomes were evaluated. We contrasted two groups: one with healthy pregnancies and the other with adverse pregnancy outcomes (APO), defined as the development of at least one of the following complications: gestational diabetes mellitus, hypertensive disorders of pregnancy, abnormal fetal growth, preterm delivery or preterm premature rupture of membranes. Median maternal age was 33 and 34 years old for the uncomplicated and adverse pregnancy outcomes groups, respectively. We found that women with adverse pregnancy outcomes had higher VFT (median 30 vs. 26.5 mm, p = 0.001) and SFT (median 18.9 vs. 17.1 mm, p = 0.03). However, the visceral/subcutaneous fat ratio was not statistically different between groups. Finally, we performed a subanalysis for metabolic and placental vascular dysfunction complications. After performing a multivariate logistic regression analysis adjusted for maternal age, smoking, and mean arterial pressure, both the VFT (aOR 1.03, p < 0.001) and the ratio of visceral/subcutaneous fat (aOR 1.37, p = 0.04) were significantly associated with the development of adverse pregnancy outcomes; however, the associations of VFT and the VFT-to-SFT ratio were higher for the occurrence of gestational diabetes (aOR 1.07, p < 0.001; aOR 2.09, p = 0.001; respectively) and showed no relationships with placental complications. When conducting a first-trimester ultrasound assessment, sonographers may measure VFT without additional time or cost involved. Identification of pregnant women with increased VFT (>37 mm) may benefit from a close follow-up, especially for the development of gestational diabetes, independent of BMI.
- Open Access
- 28 August 2022
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 191, 40-47
Catalase post-translational modifications as key targets in the control of erythrocyte redox homeostasis in children with obesity and insulin resistance
- 28 August 2022
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 191, 40-47
Open AccessCatalase post-translational modifications as key targets in the control of erythrocyte redox homeostasis in children with obesity and insulin resistance
- Open Access
- 5 February 2021
- Published by MDPI AG in Antioxidants
- Vol. 10 (2) , 244
Blunted Reducing Power Generation in Erythrocytes Contributes to Oxidative Stress in Prepubertal Obese Children with Insulin Resistance
Childhood obesity, and specifically its metabolic complications, are related to deficient antioxidant capacity and oxidative stress. Erythrocytes are constantly exposed to multiple sources of oxidative stress; hence, they are equipped with powerful antioxidant mechanisms requiring permanent reducing power generation and turnover. Glucose-6-phosphate dehydrogenase (G6PDH) and 6-phosphogluconate dehydrogenase (6PGDH) are two key enzymes on the pentose phosphate pathway. Both enzymes supply reducing power by generating NADPH, which is essential for maintaining the redox balance within the cell and the activity of other antioxidant enzymes. We hypothesized that obese children with insulin resistance would exhibit blunted G6PDH and 6PGDH activities, contributing to their erythrocytes’ redox status imbalances. We studied 15 control and 24 obese prepubertal children, 12 of whom were insulin-resistant according to an oral glucose tolerance test (OGTT). We analyzed erythroid malondialdehyde (MDA) and carbonyl group levels as oxidative stress markers. NADP+/NADPH and GSH/GSSG were measured to determine redox status, and NADPH production by both G6PDH and 6PGDH was assayed spectrophotometrically to characterize pentose phosphate pathway activity. Finally, superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPX) and glutathione reductase (GR) activities were also assessed. As expected, MDA and carbonyl groups levels were higher at baseline and along the OGTT in insulin-resistant children. Both redox indicators showed an imbalance in favor of the oxidized forms along the OGTT in the insulin-resistant obese group. Additionally, the NADPH synthesis, as well as GR activity, were decreased. H2O2 removing enzyme activities were depleted at baseline in both obese groups, although after sugar intake only metabolically healthy obese participants were able to maintain their catalase activity. No change was detected in SOD activity between groups. Our results show that obese children with insulin resistance present higher levels of oxidative damage, blunted capacity to generate reducing power, and hampered function of key NADPH-dependent antioxidant enzymes.
- 5 February 2021
- Published by MDPI AG in Antioxidants
- Vol. 10 (2) , 244
Open AccessBlunted Reducing Power Generation in Erythrocytes Contributes to Oxidative Stress in Prepubertal Obese Children with Insulin Resistance
Childhood obesity, and specifically its metabolic complications, are related to deficient antioxidant capacity and oxidative stress. Erythrocytes are constantly exposed to multiple sources of oxidative stress; hence, they are equipped with powerful antioxidant mechanisms requiring permanent reducing power generation and turnover. Glucose-6-phosphate dehydrogenase (G6PDH) and 6-phosphogluconate dehydrogenase (6PGDH) are two key enzymes on the pentose phosphate pathway. Both enzymes supply reducing power by generating NADPH, which is essential for maintaining the redox balance within the cell and the activity of other antioxidant enzymes. We hypothesized that obese children with insulin resistance would exhibit blunted G6PDH and 6PGDH activities, contributing to their erythrocytes’ redox status imbalances. We studied 15 control and 24 obese prepubertal children, 12 of whom were insulin-resistant according to an oral glucose tolerance test (OGTT). We analyzed erythroid malondialdehyde (MDA) and carbonyl group levels as oxidative stress markers. NADP+/NADPH and GSH/GSSG were measured to determine redox status, and NADPH production by both G6PDH and 6PGDH was assayed spectrophotometrically to characterize pentose phosphate pathway activity. Finally, superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPX) and glutathione reductase (GR) activities were also assessed. As expected, MDA and carbonyl groups levels were higher at baseline and along the OGTT in insulin-resistant children. Both redox indicators showed an imbalance in favor of the oxidized forms along the OGTT in the insulin-resistant obese group. Additionally, the NADPH synthesis, as well as GR activity, were decreased. H2O2 removing enzyme activities were depleted at baseline in both obese groups, although after sugar intake only metabolically healthy obese participants were able to maintain their catalase activity. No change was detected in SOD activity between groups. Our results show that obese children with insulin resistance present higher levels of oxidative damage, blunted capacity to generate reducing power, and hampered function of key NADPH-dependent antioxidant enzymes.
- Open Access
- 26 August 2020
- Published by MDPI AG in Antioxidants
- Vol. 9 (9) , 794
Placental Adaptive Changes to Protect Function and Decrease Oxidative Damage in Metabolically Healthy Maternal Obesity
Pregnancy-related disorders, including preeclampsia and gestational diabetes, are characterized by the presence of an adverse intrauterine milieu that may ultimately result in oxidative and nitrosative stress. This scenario may trigger uncontrolled production of reactive oxygen species (ROS) such as superoxide anion (O●−) and reactive nitrogen species (RNS) such as nitric oxide (NO), along with an inactivation of antioxidant systems, which are associated with the occurrence of relevant changes in placental function through recognized redox post-translational modifications in key proteins. The general objective of this study was to assess the impact of a maternal obesogenic enviroment on the regulation of the placental nitroso-redox balance at the end of pregnancy. We measured oxidative damage markers—thiobarbituric acid-reacting substances (TBARS) and carbonyl groups (C=O) levels; nitrosative stress markers—inducible nitric oxide synthase, nitrosothiol groups, and nitrotyrosine residues levels; and the antioxidant biomarkers—catalase and superoxide dismutase (SOD) activity and expression, and total antioxidant capacity (TAC), in full-term placental villous from both pre-pregnancy normal weight and obese women, and with absence of metabolic complications throughout gestation. The results showed a decrease in C=O and TBARS levels in obese pregnancies. Although total SOD and catalase concentrations were shown to be increased, both activities were significantly downregulated in obese pregnancies, along with total antioxidant capacity. Inducible nitric oxide sintase levels were increased in the obese group compared to the lean group, accompanied by an increase in nitrotyrosine residues levels and lower levels of nitrosothiol groups in proteins such as ERK1/2. These findings reveal a reduction in oxidative damage, accompanied by a decline in antioxidant response, and an increase via NO-mediated nitrative stress in placental tissue from metabolically healthy pregnancies with obesity. All this plausibly points to a placental adaptation of the affected antioxidant response towards a NO-induced alternative pathway, through changes in the ROS/RNS balance, in order to reduce oxidative damage and preserve placental function in pregnancy.
- 26 August 2020
- Published by MDPI AG in Antioxidants
- Vol. 9 (9) , 794
Open AccessPlacental Adaptive Changes to Protect Function and Decrease Oxidative Damage in Metabolically Healthy Maternal Obesity
Pregnancy-related disorders, including preeclampsia and gestational diabetes, are characterized by the presence of an adverse intrauterine milieu that may ultimately result in oxidative and nitrosative stress. This scenario may trigger uncontrolled production of reactive oxygen species (ROS) such as superoxide anion (O●−) and reactive nitrogen species (RNS) such as nitric oxide (NO), along with an inactivation of antioxidant systems, which are associated with the occurrence of relevant changes in placental function through recognized redox post-translational modifications in key proteins. The general objective of this study was to assess the impact of a maternal obesogenic enviroment on the regulation of the placental nitroso-redox balance at the end of pregnancy. We measured oxidative damage markers—thiobarbituric acid-reacting substances (TBARS) and carbonyl groups (C=O) levels; nitrosative stress markers—inducible nitric oxide synthase, nitrosothiol groups, and nitrotyrosine residues levels; and the antioxidant biomarkers—catalase and superoxide dismutase (SOD) activity and expression, and total antioxidant capacity (TAC), in full-term placental villous from both pre-pregnancy normal weight and obese women, and with absence of metabolic complications throughout gestation. The results showed a decrease in C=O and TBARS levels in obese pregnancies. Although total SOD and catalase concentrations were shown to be increased, both activities were significantly downregulated in obese pregnancies, along with total antioxidant capacity. Inducible nitric oxide sintase levels were increased in the obese group compared to the lean group, accompanied by an increase in nitrotyrosine residues levels and lower levels of nitrosothiol groups in proteins such as ERK1/2. These findings reveal a reduction in oxidative damage, accompanied by a decline in antioxidant response, and an increase via NO-mediated nitrative stress in placental tissue from metabolically healthy pregnancies with obesity. All this plausibly points to a placental adaptation of the affected antioxidant response towards a NO-induced alternative pathway, through changes in the ROS/RNS balance, in order to reduce oxidative damage and preserve placental function in pregnancy.